Copyright
©The Author(s) 2021.
World J Gastroenterol. Jul 28, 2021; 27(28): 4504-4535
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4504
Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4504
Table 7 Recommendations of the American Association for the Study of Liver Diseases and European Association for the Study of the Liver on the use of immunosuppressive therapies in chronic liver disease during coronavirus disease 2019
| Suggestions | |
| (1) Starting with corticosteroids and immunomodulators should proceed; and (2) Risk benefit ratio assessments should be carried out | |
| Patients on immunosuppressive treatment and not infected with COVID-19 | Decreases or adjustment of doses is not advisable |
| Patients infected with COVID-19 on immunosuppressive drugs | (1) Reduce corticosteroids dose after specialist physician (consider tapering to prevent adrenal insufficiency); and (2) Decreasing the doses of cyclosporine, mycophenolate, and azathioprine is recommended in severe COVID-19 (especially patients with lymphopenia) |
| Patients requiring initiation of immunosuppressive agents | Starting treatment is suggested in these patients regardless of COVID-19 status |
- Citation: Mohamed DZ, Ghoneim MES, Abu-Risha SES, Abdelsalam RA, Farag MA. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: Manifestations, mechanism and management. World J Gastroenterol 2021; 27(28): 4504-4535
- URL: https://www.wjgnet.com/1007-9327/full/v27/i28/4504.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i28.4504